Cystic Fibrosis Pipeline Market Research Report 2022: Comprehensive Insights About 75+ Companies and 80+ Pipeline Drugs – ResearchAndMarkets.com
March 10, 2022DUBLIN–(BUSINESS WIRE)–The “Cystic Fibrosis – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
The publisher’s, “Cystic Fibrosis – Pipeline Insight, 2022,” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Cystic Fibrosis pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cystic Fibrosis pipeline landscape is provided which includes the disease overview and Cystic Fibrosis treatment guidelines. The assessment part of the report embraces, in depth Cystic Fibrosis commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cystic Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Cystic Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Cystic Fibrosis.
Cystic Fibrosis Emerging Drugs Chapters
This segment of the Cystic Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Cystic Fibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Cystic Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Cystic Fibrosis
Major Players in Cystic Fibrosis include approx. 75+ key companies which are developing the therapies for Cystic Fibrosis. The companies which have their Cystic Fibrosis drug candidates in the most advanced stage, i.e. phase II include, Algi Pharma.
Cystic Fibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cystic Fibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cystic Fibrosis drugs.
Cystic Fibrosis Report Insights
- Cystic Fibrosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Cystic Fibrosis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Krystal Biotech
- Vertex Pharmaceuticals
- Translate Bio
- Novartis
- Algi Pharma
- Verona Pharma
- Atlantic Healthcare
- Calithera Biosciences
- Horizon Therapeutics
- Santhera Pharmaceuticals
- Reveragen Biopharma
- Spli Sense
- GlaxosmithKline
- EmphyCorp
- Abbvie
- Galapagos NV
- Vertex Pharmaceuticals
- PathBio Analytics
- AstraZeneca
- AxentisPharma AG
Key Products
- KB407
- MRT5005
- P1037
- Cavosonstat
- QBW276
- VX121
- OligoG
- Ensifentrine
- Renzapride
- CB280
- SPL84231
- Bacteriophage therapeutics
- Renzapride
- Sodium pyruvate
- GLPG 3067
- GLPG2737
- P1037
- Cavosonstat
- Brensocatib
- Ravicti
- Tobramycin
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/vftskx.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900